PhRMA @ #ASCO13: Innovation Extends, Improves and Saves Lives in the War Against Cancer

PhRMA @ #ASCO13: Innovation Extends, Improves and Saves Lives in the War Against Cancer

05.31.13 | By Jennifer Wall

The Catalyst is covering #ASCO13 this weekend and we’ll be posting ongoing thoughts on the pulse of the conference. We welcome your feedback and encourage you to leave comments below or tweet @PhRMA.   

With the American Society of Clinical Oncology’s (ASCO) annual meeting kicking off today in Chicago, we are reminded that oncology patients are living longer, healthier lives compared to years past. Over a span of approximately 30 years, the collaborative efforts of biopharmaceutical and academic scientists, federal researchers and doctors have yielded results: the five year survival rate for patients has increased by nearly 40 percent since 1980, while the cancer death rates decreased by 20 percent over the last two decades. This represents a major step forward in the war against cancer.

With this kind of progress, it is essential that we continue investing in innovation to extend, improve and save the lives of millions of patients. Sustained biopharmaceutical innovation provides hope for millions of patients suffering from disease, and the good news is that our collective work is just getting started. What do you think cancer treatments will look like in 30 more years? Share your thoughts below or tweet @PhRMA using the hashtag #ASCO13.

 

Comments

Hide Comments

More On PhRMA — powered by PhRMApedia